注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白穴位注射联合骨痛灵酊外敷在强直性脊柱炎患者中的应用效果  

Application effect of acupoint injection of Recombinant Human Tumor Necrosis Factor-αReceptorⅡ:IgG Fc Fusion Protein for Injection combined with external application of Gutongling Tincture in patients with ankylosing spondylitis

作　　者：洪仪慧 黄萍[2] 刘圣徽 HONG Yihui;HUANG Ping;LIU Shenghui(Department of Pharmacy,Jiujiang Economic and Technological Development Zone People's Hospital,Development Zone Branch of JiuJiang NO.1 People's Hospital,Jiangxi Province,Jiujiang332000,China;Department of Pharmacy,JiuJiang NO.1 People's Hospital,Jiangxi Province,Jiujiang332000,China;Department of Rheumatology and Immunology,JiuJiang NO.1 People's Hospital,Jiangxi Province,Jiujiang332000,China)

机构地区：[1]江西省九江经济技术开发区人民医院、江西省九江市第一人民医院开发区分院药剂科,江西九江332000 [2]江西省九江市第一人民医院药剂科,江西九江332000 [3]江西省九江市第一人民医院风湿免疫科,江西九江332000

出　　处：《中国当代医药》2025年第10期105-109,共5页China Modern Medicine

基　　金：江西省中医药管理局科技计划项目(2023B0430)。

摘　　要：目的探讨注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白穴位注射联合骨痛灵酊外敷在强直性脊柱炎患者中的应用效果。方法选取2021年4月至2024年4月九江市第一人民医院风湿免疫科收治的212例强直性脊柱炎患者作为研究对象,按照不同治疗方式分为联合组(108例)与对照组(104例)。联合组采用注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白穴位注射联合骨痛灵酊外敷方法,对照组采用骨痛灵酊外敷方法。比较两组患者的治疗效果、疼痛程度、Bath强直性脊柱炎功能指数(BASFI)、Bath强直性脊柱炎病情活动性指数(BASDAI)、炎症指标[基质金属蛋白酶-3(MMP-3)、骨形态发生蛋白-2(BMP-2)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)]、不良反应情况。结果联合组治疗2、6、12周后视觉模拟评分法(VAS)评分低于对照组,差异有统计学意义(P<0.05)。联合组治疗后总有效率高于对照组,BASFI、BASDAI评分及BMP-2、MMP-3、CRP和TNF-α水平低于对照组,差异有统计学意义(P<0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论强直性脊柱炎患者采用注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白穴位注射与骨痛灵酊外敷联合治疗,可提高治疗效果,缓解疼痛,改善BASDAI评分,降低炎症因子水平,提升脊柱功能,安全性良好。Objective To investigate the effect of acupoint injection of Recombinant Human Tumor Necrosis Factor-αReceptorⅡ:IgG Fc Fusion Protein for Injection combined with external application of Gutongling Tincture in patients with ankylosing spondylitis.Methods A total of 212 patients with ankylosing spondylitis admitted to the Department of Rheumatology and Immunology of JiuJiang NO.1 People's Hospital from April 2021 to April 2024 were selected as the research objects,and they were divided into combination group(108 cases)and control group(104 cases)according to different treatment methods.Acupoint injection of Recombinant Human Tumor Necrosis Factor-αReceptorⅡ:IgG Fc Fusion Protein for Injection combined with Gutongling Tincture was used in combination group,and Gutongling Tincture was used in control group.The therapeutic effect,pain degree,Bath ankylosing spondylitis functional index(BASFI),Bath ankylosing spondylitis disease activity index(BASDAI),inflammatory indexes(matrix metalloproteinase-3[MMP-3],bone morphogenetic protein-2[BMP-2],tumor necrosis faction-α[TNF-α],C-reactive protein[CRP]),adverse reactions were compared between the two groups.Results After 2,6 and 12 weeks of treatment,the visual analogue scale(VAS)scores of the combination group were lower than those of the control group,and the differences were statistically significant(P<0.05).After treatment,the total effective rate of combination group was higher than that of control group,and the BASFI,BASDAI scores and the levels of BMP-2,MMP-3,CRP and TNF-αwere lower than those of control group,with statistical significances(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of acupoint injection of Recombinant Human Tumor Necrosis Factor-αReceptorⅡ:IgG Fc Fusion Protein for Injection and Gutongling Tincture can improve the therapeutic effect,relieve pain,improve BASDAI score,reduce the level of inflammatory factors,improve spinal function and safe

关 键 词：注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 穴位注射 骨痛灵酊 强直性脊柱炎 血清炎症因子 Bath强直性脊柱炎病情活动性指数 

分 类 号：R593.23[医药卫生—内科学]